Navigation Links
Patent awarded for method to dampen immune response
Date:1/18/2011

National Jewish Health has been issued a US patent claiming a method to desensitize B cells by inactivating antigen receptors on their surfaces. The method, discovered by John Cambier, PhD, Chairman of the Integrated Department of Immunology at National Jewish Health, holds promise for treatment of B-cell mediated diseases, such as lymphoma and leukemia, rheumatoid arthritis, lupus and rejection of organ transplants. This therapeutic approach has the potential advantage of inactivating B cells instead of killing them as current treatments do. Therefore, this potential therapy could be more rapidly adjusted in response to the changing needs of patients.

B cells are a crucial part of the adaptive immune response, responsible for making antibodies that can neutralize and destroy pathogens. Several diseases, however, are associated with malfunction of B cells. For example, B cells can turn cancerous in diseases such as lymphoma and leukemia. In autoimmune diseases, such as rheumatoid arthritis or lupus, B cells turn against their own bodies and attack their tissues. B cells can also attack transplanted organs, which they recognize as foreign and potentially harmful.

The recently issued patent describes a method to inactivate B cells by disassembling their B-cell receptors. B cells begin producing antibodies after their B-cell receptors encounter foreign protein fragments, known as antigens. The B-cell receptor contains two distinct subunits; a receptor, which engages antigens, and a transducer, which transmits an activating signal to the interior of the cell.

About a decade ago, Dr. Cambier's laboratory, discovered that the two subunits could be separated, which disables the B cell's ability to recognize antigens and produce antibodies. In 2003, National Jewish Health received a patent (#6,503,509) for this method of B -cell desensitization. The most recent patent (#7,825,224) related to this technology claims the use of antibodies that bi
'/>"/>

Contact: William Allstetter
allstetterw@njhealth.org
303-398-1002
National Jewish Health
Source:Eurekalert

Page: 1 2

Related medicine news :

1. National Jewish Health receives patent for diagnostic method of autoimmune chronic urticaria
2. National Jewish Health receives patent for liposome-based vaccine
3. K-State receives patent for noncontroversial source of stem cells
4. 15 new US patents awarded this past year to NJIT researchers
5. UR discovers new way to boost vaccines, seeks patent
6. Brookhaven Lab and BioSET Inc. patent improved growth factor technology
7. USF receives patent for technology to improve treatment for neurodegenerative diseases
8. Quincy Bioscience Receives Patent for Jellyfish Protein Aequorin
9. Greenway Awarded U.S. Patent For EHR Functionality and Workflow
10. Volumetrics Medical Imaging, LLC and Medison Co., Ltd. Announce Technology License and Settlement of Patent Litigation
11. Mobile and Patented: DATA-TO-CAMERA TOGGLE on handheld device replaces old camera and clipboard approach everywhere! Beats IPAD to camera punch too.....
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... Dallas, TX (PRWEB) November 22, 2014 ... Society (ICS) as the complaint that the individual ... times for voiding. The report “Nocturia – Pipeline ... therapeutic development for Nocturia, complete with comparative analysis ... mechanism of action (MoA), route of administration (RoA) ...
(Date:11/22/2014)... York, New York (PRWEB) November 22, 2014 ... of power morcellators ( http://www.morcellatorlawsuit2015.com ) in minimally-invasive ... 450 new signatures since the end of October, Bernstein ... had signed the petition as of November 21st, 2014. ... 31st, when 86,042 supporters had signed on to the ...
(Date:11/22/2014)... wide variety and complexity of foods served at holiday ... allergies, an expert warns. "Every person is different ... that it can be really difficult to avoid all ... allergy and clinical immunology at Wake Forest Baptist Medical ... you know you have food allergies, caution should overrule ...
(Date:11/22/2014)... York, New York (PRWEB) November 22, 2014 ... filed on behalf of patients who allegedly developed Type ... forward in the federal multidistrict litigation now underway in ... LLP reports. According to court documents, the litigation will ... 10:00 a.m. The Court has directed Lead Counsel for ...
(Date:11/22/2014)... Hastings and Hastings, a discount accident attorney in ... with the option of leaving an online review using ... and easy to navigate website that has recently been ... allows clients to research the Hastings and Hastings law ... when retaining an attorney. Those who have been injured ...
Breaking Medicine News(10 mins):Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 3Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 4Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 2Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 3Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 4Health News:'Tis the Season of Challenges for Those With Food Allergies 2Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 2Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 3Health News:Hastings and Hastings Announces Providing Clients with the Option of Leaving an Online Review Using Google + 2Health News:Hastings and Hastings Announces Providing Clients with the Option of Leaving an Online Review Using Google + 3
... treatment for women that cuts off blood flow to ... appropriate treatment for women in a Clinical Therapeutics article ... England Journal of Medicine . "UFE (also called ... and minimally invasive option for women to consider. This ...
... , SAN FRANCISCO, Aug. 13 Nile Therapeutics, ... of novel therapeutics for heart failure patients, today announced its second quarter ... , , For the second quarter of 2009, ... share, compared to a net loss of approximately $3.8 million, or $0.16 ...
... , , DENVER, Aug. ... BDMS ) , operators of PERFECT TEETH ... and six months ended June 30, 2009. For the quarter ended ... 2.0%, to $15.2 million. Net revenue increased $93,000, or 1.1%, to ...
... areas of the brain needed to perceive feelings, study ... drinking can affect the ability to recognize other people,s ... used functional MRI to monitor brain activity in 15 ... faces with positive or negative emotional expressions. The brain ...
... , GUANGZHOU, China, Aug. 13 ... Medicine" or "the Company"), a developer,and a leading distributor ... (TCM), nutritional and dietary supplements, and,medical devices and medical ... Second Quarter 2009 Highlights:, ...
... , New England Journal of Medicine Highlights ... Decrease Hysterectomy Rate in United States , , ... invasive interventional radiology treatment for women that cuts off blood flow ... treatment for women in a Clinical Therapeutics article in the Aug. ...
Cached Medicine News:Health News:Interventional radiology treatment for uterine fibroids: Safe, nonsurgical option 2Health News:Interventional radiology treatment for uterine fibroids: Safe, nonsurgical option 3Health News:Nile Therapeutics Reports 2009 Second Quarter Financial Results 2Health News:Nile Therapeutics Reports 2009 Second Quarter Financial Results 3Health News:Nile Therapeutics Reports 2009 Second Quarter Financial Results 4Health News:Birner Dental Management Services, Inc. Announces Earnings Per Share Up 33% for 2nd Quarter 2009 2Health News:Birner Dental Management Services, Inc. Announces Earnings Per Share Up 33% for 2nd Quarter 2009 3Health News:Birner Dental Management Services, Inc. Announces Earnings Per Share Up 33% for 2nd Quarter 2009 4Health News:Birner Dental Management Services, Inc. Announces Earnings Per Share Up 33% for 2nd Quarter 2009 5Health News:Birner Dental Management Services, Inc. Announces Earnings Per Share Up 33% for 2nd Quarter 2009 6Health News:Birner Dental Management Services, Inc. Announces Earnings Per Share Up 33% for 2nd Quarter 2009 7Health News:Birner Dental Management Services, Inc. Announces Earnings Per Share Up 33% for 2nd Quarter 2009 8Health News:Birner Dental Management Services, Inc. Announces Earnings Per Share Up 33% for 2nd Quarter 2009 9Health News:Birner Dental Management Services, Inc. Announces Earnings Per Share Up 33% for 2nd Quarter 2009 10Health News:Boozing Blunts Ability to Read Faces 2Health News:China Medicine Announces Second Quarter 2009 Results 2Health News:China Medicine Announces Second Quarter 2009 Results 3Health News:China Medicine Announces Second Quarter 2009 Results 4Health News:China Medicine Announces Second Quarter 2009 Results 5Health News:China Medicine Announces Second Quarter 2009 Results 6Health News:China Medicine Announces Second Quarter 2009 Results 7Health News:China Medicine Announces Second Quarter 2009 Results 8Health News:China Medicine Announces Second Quarter 2009 Results 9Health News:China Medicine Announces Second Quarter 2009 Results 10Health News:China Medicine Announces Second Quarter 2009 Results 11Health News:China Medicine Announces Second Quarter 2009 Results 12Health News:China Medicine Announces Second Quarter 2009 Results 13Health News:China Medicine Announces Second Quarter 2009 Results 14Health News:Interventional Radiology Treatment for Uterine Fibroids: Safe, Nonsurgical Option 2Health News:Interventional Radiology Treatment for Uterine Fibroids: Safe, Nonsurgical Option 3Health News:Interventional Radiology Treatment for Uterine Fibroids: Safe, Nonsurgical Option 4Health News:Interventional Radiology Treatment for Uterine Fibroids: Safe, Nonsurgical Option 5
(Date:11/21/2014)... Nov. 21, 2014 Clementia ... Medicines Agency (EMA) has granted Orphan Medicinal ... product candidate, for the treatment of fibrodysplasia ... severely disabling genetic disease characterized by painful, ... and new abnormal bone formation. This process, ...
(Date:11/21/2014)... IRVINE, Calif. , Nov. 20, 2014  Edwards ... leader in the science of heart valves and hemodynamic ... corporate giving in 2014 to support a strong launch ... Heartbeat Matters , and to improve the global communities ... In 2014, Edwards, global corporate giving will exceed $8 ...
(Date:11/21/2014)... /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: CMN ) announced today ... be presenting at the 26 th Annual Piper Jaffray ... New York . The formal presentation is scheduled ... addition, Mr. Krakauer and Jorgen B. Hansen , President ... the day. An audio webcast will be ...
Breaking Medicine Technology:Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 2Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 3Edwards Lifesciences Increases Charitable Giving In 2014 To Support Launch Of Every Heartbeat Matters 2
The original battery-operated suction and irrigation system features a new ergonomic hand piece and superior performance characteristics that have increased the overall flow rate....
... the best of both worlds, the ... is the latest addition to the ... bipolar cautery instruments for ophthalmic surgery. ... extrusion aspiration and backflush functionality in ...
...
...
Medicine Products: